Post-finasteride syndrome - a true clinical entity?

Int J Impot Res. 2025 Jun;37(6):426-435. doi: 10.1038/s41443-025-01025-6. Epub 2025 Feb 14.

Abstract

This review critically examines Post-Finasteride Syndrome (PFS), a condition eventually reported by men who have used finasteride for androgenetic alopecia or benign prostatic enlargement and experienced persistent adverse effects after discontinuation. We explore the clinical manifestations, including sexual dysfunction, neuropsychiatric symptoms, and physical changes, that collectively challenge both diagnosis and management. This review evaluates the evidence for PFS, discusses potential mechanisms including neurobiological alterations, genetic predispositions, and addresses the controversies surrounding its existence and recognition by the medical community. Emphasis is placed on the role of patient education and the need for thorough risk assessment before prescribing finasteride. Although contrasting data from literature, men treated with finasteride could develop a plethora of non-neglectable physical and psychological symptoms identifying PFS. A multidisciplinary approach to research, policy-making, and patient advocacy is essential to better understand, diagnose, and manage PFS, underlining the necessity for greater awareness and scientific inquiry into this contentious and impactful syndrome.

Publication types

  • Review

MeSH terms

  • 5-alpha Reductase Inhibitors* / adverse effects
  • Alopecia / drug therapy
  • Finasteride* / adverse effects
  • Finasteride* / therapeutic use
  • Humans
  • Male
  • Prostatic Hyperplasia / drug therapy
  • Sexual Dysfunction, Physiological / chemically induced
  • Syndrome

Substances

  • Finasteride
  • 5-alpha Reductase Inhibitors